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Loss-of-Function Mutations in HPSE2
Cause the Autosomal Recessive Urofacial Syndrome
Junfeng Pang,1,9 Shu Zhang,2,9 Ping Yang,1,2 Bobbilynn Hawkins-Lee,1 Jixin Zhong,1,2 Yushan Zhang,1
Bernardo Ochoa,3 Jose A.G. Agundez,4 Marie-Antoinette Voelckel,5 Weikuan Gu,6 Wen-Cheng Xiong,7
Lin Mei,7 Jin-Xiong She,1,* and Cong-Yi Wang1,8,*
Previously, we localized the defective gene for the urofacial syndrome (UFS) to a region on chromosome 10q24 by homozygosity
mapping. We now report evidence that Heparanse 2 (HPSE2) is the culprit gene for the syndrome. Mutations with a loss of function
in the Heparanase 2 (HPSE2) gene were identiﬁed in all UFS patients originating from Colombia, the United States, and France.
HPSE2 encodes a 592 aa protein that contains a domain showing sequence homology to the glycosyl hydrolase motif in the heparanase
(HPSE) gene, but its exact biological function has not yet been characterized. Complete loss of HPSE2 function in UFS patients suggests
that HPSE2 may be important for the synergic action of muscles implicated in facial expression and urine voiding.The urofacial syndrome (UFS [MIM 236730]) is an auto-
somal recessive disease characterized by urological and
facial abnormalities.1,2 The typical symptom for UFS
patients is a distorted face, as if in pain or sadness, when
they smile or laugh. However, dysfunctional voiding, such
as repeated episodes of urinary tract infection, dysuria or
incontinence, frequency, urgency, or enuresis, is the life-
threatening component of the syndrome. This gradually
progresses to severe upper tract damage and the develop-
ment of bladder trabeculation, vesicoureteral reﬂux (VUR),
hydroureternephrosis, and subsequent renal failure.1–3
Nevertheless, no apparent neurological or urinary obstruc-
tive pathology has been noticed in any UFS patients.
Previous studies in patients originating from Colombia
localized the disease gene to a region on chromosome
10q24 by homozygositymapping.4,5 Subsequent ﬁnemap-
ping provided preliminary evidence that the disease gene
could be located in a genomic interval of approximately
250 kb DNA between markers D10S2500 and D10S2511.6
Mutation screening in UFS patients was also carried out
in two candidate genes, GOT1 (MIM 138180) and CNNM1
(ancient conserved domain protein 1, ACDP1) (MIM
607802).5–7 GOT1 contains 9 exons and spans 33.7 kb of
genomic DNA. It is a ubiquitous pyridoxal phosphate-
dependent enzyme, and it plays an important role in
amino acid metabolism and in the urea/tricarboxylic acid
cycles. CNNM1 contains 11 exons and spans a genomic
region of 67.56 kb DNA sequence. CNNM1 is a novel
gene belonging to a new gene family that could be impli-
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The Ameological mutation was discovered in these two plausible
candidate genes, raising the possibility that the disease
gene may be outside of the reﬁned interval. This was
a distinct possibility, because it is sometimes difﬁcult to
distinguish between recombination events and point
mutations in homozygosity mapping.
To accurately redeﬁne the disease interval, we selected
multiple families with recombination events on both
ends of the disease interval, which includes patient II.1 of
UFS-30 collected in the United States and patients II.1 of
UFS-2, II.1 of UFS-12, II.1 of UFS-13, IV.1 of UFS-14, V.1
of UFS-15, and II.1 of UFS-18, recruited from Colombia
(Figure 1). Because these patients carry two identical dis-
ease chromosomes inherited from their parents, they
were homozygous for the markers in the region without
recombination. Haplotype analysis was then carried out
to determine the disease interval. As shown in Figure 2,
chromosomal regions for each patient without recombina-
tion (markers with homozygous genotypes) were boxed.
Heterozygous genotypes were characterized in patients
II.1 of UFS-2, II.1 of UFS-13, II.1 of UFS-18, and II.1 of
UFS-30 at marker D10S1433 and its adjacent telomeric
markers, indicating that D10S1433 deﬁnes the telomeric
boundary for the disease interval. Similarly, patients II.1
of UFS-3, II.1 of UFS-12, IV.1 of UFS-14, and V.1 of UFS-15
showed heterozygous genotypes at marker D10S603 and
other centromeric markers, demonstrating that D10S603
could be the breakpoint for centromeric recombination.
Therefore, the disease region was placed at an expanded
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Figure 1. Pedigrees Used for Redefining UFS Interval and Candidate Gene Mutation Screenings
Pedigrees of UFS-2, -12, -13, -14, -15, and -18 were collected fromColombia, pedigrees UFS-30 andUFS-31 were recruited from the United
States, and pedigree UFS-50 was obtained from France. Patients of UFS-30 and UFS-31 share a common Irish heritage, and patients in
pedigree UFS-50 are of European descent. Of note, patients in pedigrees UFS-2, -12, -13, -18, -30, -31, and -50 were from unrelated
marriages, whereas patients in pedigrees UFS-14 and -15 were from consanguineous marriages.Seventeen known genes and two unnamed transcripts
(LOC100289312 and NCRNA00093) were characterized
within this newly deﬁned disease interval (Figure 3).
Mutation screening was then carried out for the 14 new
genes and the two above indicated unnamed transcripts
located in the centromeric region of the interval between
D10S198 and D10S603. We selected three patients, origi-
nating from Colombia (II.1 of UFS-2), the United StatesD10S564 5 3 5 2 3 5 2 2 5 5 5 5
UFS-2
II.1
UFS-13
II.1
UFS-18
II.1
UFS-30
II.1
UFS-12
II.1
UFS-14
IV.1
D10S185
D10S677
D10S520
D10S1433
6 9 6 6 6 6 3 1 6 6 6 6
2 2 1 2 2 3 3 2 2 2 2 2
3 5 7 6 3 5 2 3 5 5 5 5
6 7 6 7 6 3 6 7 6 6 6 6
D10S184
D10S1726
D10S198
2 2 2 2 2 2 3 3 2 2 2 2
3 3 3 3 3 3 5 5 3 3 3 3
3 3 3 3 3 3 2 2 3 3 3 3
D10S603
D10S192
D10S1663
D10S1682
5 5 5 5 5 5 1 5 5 8 4 5
3 6 6 6 6 6 4 1 6 5 9 6
1 1 1 5 1 1 3 1 5 1 1 5
4 6 3 3 3 3 5 2 6 3 3 3
958 The American Journal of Human Genetics 86, 957–962, June 11,(II.1 of UFS-30), and France (II.1 of UFS-50), with each rep-
resenting a disease haplotype (mutation), except for II.1 of
UFS-50, who inherited two different disease haplotypes
from his parents. We also included a pooled control DNA
(equal amount of DNA pooled from eight normal individ-
uals) to evaluate normal polymorphisms. We designed
a PCR walking strategy, with each PCR ﬂanking a
600–800 bp of genomic region. The screenings have3 3
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Figure 2. Redefined UFS Interval Based on Haplo-
type Analysis of Patients with Recombination Events
Patients II.1 of UFS-2, II.1 of UFS-13, II.1 of UFS-18,
II.1 of UFS-12, IV.1 of UFS-14, and V.1 of UFS-15
were Colombian, whereas II.1 of UFS-30was a United
States patient. Markers with the homozygous geno-
type were boxed to deﬁne the region without recom-
bination. Alleles for markersD10S1443 andD10S603
in patients with recombination events are in bold to
show the telomeric and centromeric breakpoints,
respectively. The disease interval was placed between
markers D10S1433 and D10S603.
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Figure 3. A Transcriptional Map for the Newly Defined UFS Disease Interval
Top: a detailed genomic structure for the HPSE2 gene. Bottom: all candidate genes located between D10S1433 and D10S603. The size in
genomic DNA (kb) for each transcript is shown within the ﬁgure. The order and genomic location of each microsatellite marker within
the map was deﬁned based on the genomic sequence information from the Ensemble database. The letters represent the following: A,
HPSE2 (NM_021828); B, CNNM1 (NM_020348); C, GOT1 (NM_002079); D, NKX2-3 (NM_145285); E, SLC25A28 (NM_031212); F,
LOC100289312 (NM_002343029); G, ENTPD7 (NM_020354); H, COX15 (NM-078470); I, CUTC (NM-015960); J, ABCC2
(NM_000392); K, DNMBP (NM_015221); L, NCRNA00093 (NR_024130); M, CPN1 (NM_001308); N, ERLIN1 (NM_006459); O,
CHUK (NM_001278); P, CWF19L1 (NM_018294); Q, SNORA12 (NR_002954); R, BLOC1S2 (NM_0173809); S, PKD2L1 (NM_016112).covered 4 kb of genomic DNA ﬂanking the promoter
region and 50 UTR region, entire exons, 120 bp of exon/
intron junctions, and the 30 UTR region of each candidate
gene. Unfortunately, we were not able to identify any
apparent pathological mutation in these genes (data not
shown).
Finally, we turned our attention to the region telomeric
to CNNM1 (ACDP1), which contains a single gene
(HPSE2) that spans 776 kb of genomic DNA (Figure 3).
A homozygous nonsense mutation (c.1516C>T) was ﬁrst
identiﬁed in exon 11 of the HPSE2 gene in the Colombian
patient (Figure 4A). This mutation, designated R506X
(c.1516C>T), produces a truncated protein that misses 86
amino acids at the C terminus of the HPSE2 protein. The
mutation abolishes the TaqI restriction site that is present
in the wild-type DNA. PCR ampliﬁcation followed by
TaqI digestion was used for rapid genotyping of the 31
other UFS patients in our collection. As expected from
the haplotype data on these patients, all UFS patients from
Colombia are homozygous for the R506X (c.1516C>T)
mutation (data not shown).
We then screened mutations for the rest of the UFS
patients. Patients from two United States pedigrees (II.1
of UFS-30 and II.1 of UFS-31) with a common Irish heritage
share one same disease haplotype. Unlike the Colombian
patients, these two patients carry a homozygous 2 bp dele-
tion (c.1465_1466delAA) in exon 10 at nucleotide posi-
tions 1465 and 1466 (start codon as position 1) (Figure 4B),
resulting in a larger protein of 613 aa, with a completely
different sequence for the last 125 aa because of reading
frame shift. Of note, these patients carry a point mutationThe Ameat marker D10S2499 that was previously used to deﬁne the
centromeric boundary.6
Unlike the homozygous mutations characterized in the
above patients, two French patients (II.1 and II.3 of
UFS-50) from the same family of European decent carry
two different disease haplotypes originating from their
nonconsanguineous parents (Figure 1): the ﬁrst is identical
to the United States haplotype, and the second is unique to
the French patients. As expected, compound heterozygous
loss-of-function mutations were characterized in these two
patients. One is the same 2 bp deletion mutation found in
the United States patients (c.1465_1466delAA), whereas
the other is a 2 bp deletion mutation (c.241_242delCT)
in exon 1 at nucleotide positions 241 and 242 (start codon
as position 1) (Figure 4C).
The full-length HPSE2 gene consists of 2353 bp of nucle-
otides encoding a protein of 592 aa that contains a region
showing sequence homology to the glycosyl hydrolase
motif in the heparanase (HPSE) gene,11 but its exact biolog-
ical function has not yet been characterized. Interestingly,
phylogenetic analysis revealed that no HPSE2 orthologs
exist in species of nonvertebrates such as Drosophila mela-
nogaster (see Figure S1 available online). HPSE2 is evolu-
tionarily conserved among diverse vertebrates. For exam-
ple, the similarity between mouse and human is 93%
for the DNA coding sequence and 97% at the protein
sequence level (Figure S2).
Because of the involvement of both the urinary system
and the facial muscles for the UFS phenotype, it has been
thought that UFS may result from defects in a region of
the brain that controls micturation and facial muscle.1,3,12rican Journal of Human Genetics 86, 957–962, June 11, 2010 959
Figure 4. Mutations Identified in UFS Patients
(A) All Colombian patients share one identical disease haplotype and carry a homozygous nonsense mutation c.1516C>T (R506X) in
exon 11.
(B) The United States patients possess one identical disease haplotype and carry a homozygous AA deletion (c.1465_1466delAA) in exon
10 at nucleotide positions 1465 and 1466 (start codon as position 1).
(C) The French patients carry two different disease haplotypes: the ﬁrst is identical to the United States patients, and the second is
different from other patients. They carry a 2 bp AA deletion (c.1465_1466delAA) in exon 10, like the United States patients, and
a 2 bp CT deletion (c.241_242delCT) in exon 1 at positions 241 and 242 (start codon as position 1).Contrary to this hypothesis, cranial MRI analysis of UFS
patients showed negative results for lesions in the brain,
and MRI analysis further demonstrated a normal spine
and conusmedularis in the UFS patients, suggesting a non-
neurological origin for the disease pathogenesis.3,13 Fur-
thermore, RT-PCR analysis failed to detect HPSE2 expres-
sion in the brain and spinal cord. On the contrary, both
the facial muscle and urinary bladder showed high levels960 The American Journal of Human Genetics 86, 957–962, June 11,of HPSE2 expression. However, unlike urinary bladder,
very low levels of HPSE2 mRNA were detected in the
stomach and intestine, and, unlike facial muscle, HPSE2
was almost completely absent in the skeletal muscle
(data not shown). Given the phenotypic characteristics
of UFS patients (they show distorted facial expression
and detrusor-sphincter dyssynergia), our results suggest
that HPSE2 could regulate the coordinated action of2010
muscles implicated in facial expression and urine voiding
in the periphery. Moreover, the characterization of the
HPSE2 gene for the syndrome has now paved the way to
fully dissect the underlying mechanisms for the puzzling
observations on the clinical phenotype of patients with
this devastating disease.
In summary, this study identiﬁed three loss-of-function
mutations in theHPSE2 gene in UFS patients frommultiple
countries, which provides evidence for the conclusion that
HPSE2 is the culprit gene responsible for the syndrome.
Voiding disorders such as frequency, urgency, enuresis,
dysuria or incontinence without apparent neurological
abnormality, and urinary obstruction are highly prevalent
in the general population but are greatly underrecognized
and underreported.12,14–19 Because UFS patients share clin-
ical, radiological, and urodynamic features with those
patients with dysfunctional voiding in the general popula-
tion,3,13,20–22 it will be interesting to determine whether
altered HPSE2 function is implicated in the pathogenesis
of general voiding disorders.Supplemental Data
Supplemental Data include two ﬁgures and one table and can be
found with this article online at http://www.ajhg.org.Acknowledgments
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